325 related articles for article (PubMed ID: 21265930)
1. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
Damasiewicz MJ; Toussaint ND; Polkinghorne KR
Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
5. FGF23 and mineral metabolism, implications in CKD-MBD.
Rodríguez M; López I; Muñoz J; Aguilera-Tejero E; Almaden Y
Nefrologia; 2012 May; 32(3):275-8. PubMed ID: 22592418
[No Abstract] [Full Text] [Related]
6. Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy.
Westerberg PA; Ljunggren O; Larsson TE; Wadström J; Linde T
Nephrol Dial Transplant; 2010 Dec; 25(12):4068-71. PubMed ID: 20525976
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
[TBL] [Abstract][Full Text] [Related]
8. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
9. New insights into the role of fibroblast growth factor 23 in chronic kidney disease.
Nakai K; Komaba H; Fukagawa M
J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451
[TBL] [Abstract][Full Text] [Related]
10. What would we like to know, and what do we not know about fibroblast growth factor 23?
Cozzolino M; Galassi A; Apetrii M; Covic A
J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
[TBL] [Abstract][Full Text] [Related]
11. Emerging topics in pediatric bone and mineral disorders 2008.
McKay CP; Portale A
Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
[TBL] [Abstract][Full Text] [Related]
12. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
13. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
14. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
[TBL] [Abstract][Full Text] [Related]
15. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Heine GH; Seiler S; Fliser D
Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
Block GA
Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease--mineral and bone disorder: a complex scenario.
Mejía N; Roman-García P; Miar AB; Tavira B; Cannata-Andía JB
Nefrologia; 2011; 31(5):514-9. PubMed ID: 21959717
[TBL] [Abstract][Full Text] [Related]
18. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism.
Bortotolotto LA; Costa-Hong V; Jorgetti V; Consolim-Colombo F; Rosa K; Silva BC; Krieger EM; De Lima JJ
J Nephrol; 2007; 20(1):66-72. PubMed ID: 17347976
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23--structure, function and role in kidney diseases.
Kocełak P; Olszanecka-Glinianowicz M; Chudek J
Adv Clin Exp Med; 2012; 21(3):391-401. PubMed ID: 23214203
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of FGF-23 in chronic kidney disease.
Seiler S; Heine GH; Fliser D
Kidney Int Suppl; 2009 Dec; (114):S34-42. PubMed ID: 19946326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
